Summary
GlobalData's pharmaceutical and healthcare report offering, "Pneumonia-Drug Pipeline Analysis and Market Forecasts to 2016". is an essential source of information and analysis on the global pneumonia market. The report identifies the key trends shaping and driving the global pneumonia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global pneumonia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's analysis suggests that the global pneumonia market was worth $1.4 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 4.3% for the next seven years to reach $1 billion by 2016. The projected decline rate is primarily attributable to the patent expiries of Levaquin, Avelox and Zyvox by the end of the forecast period. Increases in the treatment seeking population, the diagnosis population and the ever-increasing development of bacterial resistance to marketed antibiotics are expected to sustain the pneumonia market.

Scope
The scope of the report includes:
-Annualized global pneumonia market revenues data from 2000 to 2009, forecast for seven years to 2016.
-Key geographies covered in this report include the Unites States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action are cell wall synthesis inhibitors, protein synthesis inhibitors and topoisomerase II and topoisomerase IV inhibitors.
-Analysis of the current and future market competition in the global pneumonia market. The key market players covered are AstraZeneca, Pfizer, Bayer, GSK and J&J Pharmaceuticals.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
-Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future pneumonia market.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global pneumonia market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global pneumonia market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global pneumonia market landscape? -Identify, understand and capitalize.

Table of Contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Pnemonia Therapeutics Market: Market Characterization 5
2.1 Overview 5
2.2 Pneumonia Therapeutics Market Size 8
2.3 Pneumonia Therapeutics Market Forecast and CAGR 9
2.4 Drivers and Barriers for the Pneumonia Therapeutics Market 10
2.4.1 Drivers for the Pneumonia Therapeutics Market 10
2.4.2 Barriers for the Pneumonia Therapeutics Market 11
2.5 Opportunity and Unmet Need 12
2.6 Key Takeaway 14
3 Pneumonia Therapeutics Market: Competitive Assessment 15
3.1 Overview 15
3.2 Strategic Competitor Assessment 15
3.3 Product Portfolio for Major Marketed Products in the Pneumonia Therapeutics Market 16
3.3.1 Zyvox (linezolid) 16
3.3.2 Zosyn (piperacillin and tazobactam) 17
3.3.3 Levaquin (levofloxacin) 18
3.3.4 Avelox (moxifloxacin) 19
3.3.5 Omnicef (cefdinir) 21
3.3.6 Tygacil (tigecycline) 21
3.3.7 Doribax (doripenem) 22
3.4 Key Takeaway 23
4 Pneumonia Therapeutics Market: Pipeline Assessment 24
4.1 Overview 24
4.2 Strategic Pipeline Assessment 24
4.2.1 Technology Trends Analytical Framework 24
4.3 Pneumonia Therapeutics-Promising Drugs under Clinical Development 26
4.4 Molecule Profiles for Promising Drugs under Clinical Development 26
4.4.1 Ceftaroline 26
4.4.2 Ceftobiprole medocaril 27
4.4.3 Restanza (cethromycin) 28
4.4.4 Vibativ (telavancin) 29
4.5 Pneumonia Therapeutics Market-Pipeline Assessment by Mechanism of Action 30
4.6 Pneumonia Therapeutics Market-Pipeline Assessment by Phase of Clinical Development 31
4.6.1 Pneumonia Therapeutics-Phase III Clinical Pipeline 31
4.6.2 Pneumonia Therapeutics-Phase II Clinical Pipeline 32
4.6.3 Pneumonia Therapeutics-Phase I Clinical Pipeline 33
4.6.4 Pneumonia Therapeutics-Preclinical Pipeline 33
4.6.5 Pneumonia Therapeutics-Discovery Pipeline 33
4.7 Discontinued/Suspended Drugs for Pneumonia 34
4.8 Key Takeaway 34
5 Pneumonia Therapeutics Market: Implications for Future Market Competition 35
6 Pneumonia Therapeutics Market: Future Players in the Pneumonia Therapeutics Market 36
6.1 Forest Laboratories, Inc. 36
6.1.1 Company Overview 36
6.1.2 Ceftaroline 37
6.2 Basilea Pharmaceutica 37
6.2.1 Company Overview 37
6.2.2 Ceftobiprole medocaril 38
6.3 Advanced Life Sciences 39
6.3.1 Company Overview 39
6.3.2 Restanza (cethromycin) 39
6.4 Theravance, Inc. 40
6.4.1 Company Overview 40
6.4.2 Vibativ (telavancin) 40
7 Pneumonia Therapeutics Market: Appendix 42
7.1 Definitions 42
7.2 Acronyms 42
7.3 Research Methodology 43
7.4 Coverage 44
7.5 Secondary Research 45
7.6 Primary Research 45
7.7 Models 45
7.8 Forecasts 46
7.9 Expert Panels 46
7.10 Sources 46
7.11 GlobalData Consulting 46
7.12 Contact Us 47
7.13 Disclaimer 47

List of Tables
1.1 List of Tables
Table 1: Empirical Antimicrobial Therapy for Pneumonia, 2010 7
Table 2: Pneumonia Therapeutics Market, Global, Revenues ($m), 2001-2009 9
Table 3: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 10
Table 4: Cure Rates of Zyvox in Nosocomial Pneumonia, 2010 17
Table 5: Cure Rates of Zyvox in Community-Acquired Pneumonia due to MDRSP, 2010 17
Table 6:    Pneumonia Therapeutics Market, Global,  Most Promising Molecules under Clinical Development, May 2010 26
Table 7: Pneumonia Therapeutics Market, Global, Phase III Clinical Pipeline, 2010 31
Table 8: Pneumonia Therapeutics Market, Global, Phase II Clinical Pipeline, 2010 32
Table 9: Pneumonia Therapeutics Market, Global, Phase I Clinical Pipeline, 2010 33
Table 10: Pneumonia Therapeutics Market, Global, Preclinical Pipeline, 2010 33
Table 11: Pneumonia Therapeutics Market, Global, Discovery Pipeline, 2010 33
Table 12: Pneumonia Therapeutics Market, Global, List of Discontinued Drugs, 2010 34

List of Figures
1.2 List of Figures
Figure 1: Pneumonia Therapeutics Market, Global, Revenues ($m), 2001-2009 9
Figure 2: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 10
Figure 3: Pneumonia Therapeutics Market, Global, Opportunity and Unmet Need, 2010 13
Figure 4: Pneumonia Therapeutics Market, Global, Strategic Competitor Assessment of the Major Marketed Products, 2010 15
Figure 5: Pneumonia Therapeutics Pipeline, Global, Technology Trends Analytic Framework, 2010 25
Figure 6: Pneumonia Therapeutics Market, Global, Technology Trends Analytic Framework, Description-2010 25
Figure 7: Pneumonia Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action, 2010 30
Figure 8: Pneumonia Therapeutics Market, Global, Clinical Pipeline, 2010 31
Figure 9: Pneumonia Therapeutics Market, Global, Implications for Future Market Competition, 2010 35
Figure 10: Pneumonia Therapeutics Market, Global, Clinical Pipeline by Company, 2010 36
Figure 11: GlobalData Methodology, 2010 44